|
Status |
Public on Jan 09, 2014 |
Title |
Inducible expression of MyoD directly mediates myogenic conversion of human induced pluripotent stem cells (iPSCs) derived from Duchenne muscular dystrophy (DMD). |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Genome-wide gene expression analysis of MyoD-infected DMD-specific iPSCs (GM05112-M5.1) on days 0 (untreated), day 3 and day 8 post Dox treatment, human primary myoblasts (undifferentiated and as differentiated myotubes), and undifferentiated iPSCs from healthy donors (iPSCs-1 and iPSCs-2).
|
|
|
Overall design |
DMD-specific iPSCs were infected with lentivirus expressing MyoD under the control of Tet-inducible promoter and another lentivirus expressing the transactivator. To initiate myogenic differentiation, iPSCs were treated with 1µg/ml Dox. RNA was isolated 0, 3 and 8 days later and gene expression analysis was performed.
|
|
|
Contributor(s) |
Abujarour R, Robbins DL, Flynn P |
Citation(s) |
24396035 |
|
Submission date |
May 03, 2013 |
Last update date |
Mar 25, 2019 |
Contact name |
Dave Robbins |
E-mail(s) |
dave.robbins@fatetherapeutics.com
|
Organization name |
Fate Therapeutics
|
Street address |
3535 General Atomics Court Ste. 200
|
City |
San Diego |
State/province |
CA |
ZIP/Postal code |
92121 |
Country |
USA |
|
|
Platforms (1) |
GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
Samples (7)
|
GSM1133454 |
iPSCs from healthy donor (on feeders) |
GSM1133455 |
iPSCs from healthy donor (feeder-free) |
GSM1133456 |
MyoD-infected DMD-specific iPSCs (GM05112-M5.1), untreated (feeder-free) |
GSM1133457 |
MyoD-infected DMD-specific iPSCs (GM05112-M5.1), day 3 post-dox addition |
GSM1133458 |
MyoD-infected DMD-specific iPSCs (GM05112-M5.1), day 8 post-dox addition |
GSM1133459 |
Human skeletal muscle myoblasts, in expansion media |
GSM1133460 |
Human skeletal muscle myoblasts, in differentiation media (day 3) |
|
Relations |
BioProject |
PRJNA201337 |